Conference Program


Best of ASCO® Bangkok 2019

2-3 August 2019 at AVANI Riverside Bangkok Hotel BANGKOK, THAILAND

Download : PDF version (Save target as, Save link as)
       Day 1_Program BOA 2019
       Day 2_Program BOA 2019



August 2-3, 2019
AVANI Riverside
Bangkok Hotel

BANGKOK, THAILAND

Online Registrationto attend BOA Bangkok 2019


Tentative Program: Best of ASCO Bangkok 2019 (Day 1: 2nd August 2019)

Time Abstract ID Title Presenter Moderator
7:30-8:30 Trainee session
(Thai language)
Real-world tumor/ plasma genetic testing: tough choices, how do you pick? Assist.Prof.THANYANAN REUNGWETWATTANA,
NARAVAT POUNGVARIN, M.D., Ph.D.
Assoc.Prof.VIROTE SRIURANPONG
8.30-9.30 Trainee session
(Thai language)
Care of Oligometastatic Disease: Enhancing Survival or Increasing Toxicity? NAPAPAT AMORNWICHET, M.D.,
NAIYARAT PRASONGSOOK, M.D.
Assoc.Prof.CHAIYUT CHAROENTUM
9:30-9:40 Opening and welcome message Assoc.Prof.EKAPHOP SIRACHAINAN  
    Scientific Agenda Assoc.Prof.SUTHINEE ITHIMAKIN  
9:45-10:30   Symposium Bristol-Myers Squibb  : Data of immune checkpoint inhibitors in second-line NSCLC treatment: enhancement in long term survival  Prof.Neal Edward Ready,
Duke cancer institute USA
Assoc. Prof.VICHIEN  SRIMUNINNIMIT
10:30-10:50   Exhibition    
    CNS tumor and sarcoma session    
10:50-11:02 LBA3 ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS). TOUCH ATIVITAVAS, M.D. KASAN SEETALAROM, M.D.
11:02-11:14 11000 Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized clinical trial from the Italian Sarcoma Group, the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG). CHAWALIT CHAYANGSU, M.D.  
11:14-11.26 2000 Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion Assoc.Prof.SITH SATHORNSUMETEE  
11:26-11:40   Q&A  panelists   
11:45-12:30   Symposium Pfizer: Raising the Bar in Breast Cancer Care: CDK 4/6 Inhibitor Prof. Hamdy Abdel Azim
Faculty of Medicine, Cairo University, Egypt
 Assoc Prof. Chaiyut Charoentum
12:30-12:50   Exhibition    
  Early Breast cancer session  
12:50-13:00 503 Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx. Assist.Prof.THITIYA  DEJTHEVAPORN Assist.Prof.AUMKHAE  SOOKPRASERT
13:00-13:10 504 Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM). PIYAWAN TIENCHAIANANDA, M.D.  
13:10-13:20 500 Neoadjuvant trastuzumab, pertuzumab (P) and chemotherapy versus trastuzumab emtansine (TDM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer: Final outcome results from the phase III KRISTINE study Assist. Prof.CHARUWAN AKEWANLOP  
13:20-13:40 Discussion/ Q&A  Discussant:  Prof. Hamdy Abdel Azim, Q&A: panelists  
13:40-14:25   Symposium Eisai: Systemic treatment landscape for advanced hepatocellular carcinoma Dr.Zhong-Zhe Lin,
National Taiwan University Hospital, Taipei, Taiwan
Assoc.Prof.VIROTE SRIURANPONG
14:25-14:45   Exhibition     
    Non-colorectal GI cancer    Assoc.Prof.EKAPHOP SIRACHAINAN
14:45-14:55 4000 APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. KULATIDA MANEENIL, M.D.  
14:55-15:05 LBA4 Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial. Assist.Prof. SUEBPONG TANASANVIMON  
15:05-15:15 4003 ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. TEERAPAT UNGTRAKUL, M.D.   
15:15-15:35   Discussion/ Q&A  Discussant: TOUCH ATIVITAVAS, M.D.,
Q&A: panelists
 
 
    Colorectal cancer session     
15:40-15:50 3501 Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC). Assist.Prof. SUEBPONG TANASANVIMON Prof.VORACHAI RATANATHARATHORN
15:50-16:00 3508 Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC. Assist.Prof.NUTTAPONG NGAMPHAIBOON  
16:00-16:10 3504 FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. Assist.Prof. KRITTIYA KORPHAISARN  
16:10-16:30   Discussion/ Q&A  Discussant: Prof. John Allen Bridgewater, Q&A: panelists   
16:30-17:15   Symposium Amgen: Making a difference in 1st line mCRC treatment Prof. John Allen Bridgewater
UCL Cancer Institute, London, UK

Assoc.Prof.EKAPHOP SIRACHAINAN
End of day 1

Tentative Program: Best of ASCO Bangkok 2019 (Day 2: 3rd August 2019)

Time Abstract ID Title Presenter Moderator
8:00-8:45   Symposium Mylan : Management of HER2+ Breast cancer - What's changing and where are we with Biosimilar Trastuzumab? Prof.Hope Rugo
Breast Oncology and Clinical Trials Education UCSF Helen Diller Family Comprehensive Cancer Center, CA, USA
Assist.Prof. SUEBPONG TANASANVIMON
    Metastatic breast cancer session     
8:45-8:55 1003 IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). NAPA PARINYANITIKUL, M.D. Assoc. Prof.VICHIEN  SRIMUNINNIMIT
8:55-9:05 LBA1008 Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results. Assist.Prof.AUMKHAE  SOOKPRASERT  
9:05-9:15 1002 Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. Assoc.Prof.SUTHINEE ITHIMAKIN  
9:15-9:35   Discussion/ Q&A  Discussant:Prof.Hope Rugo, Q&A: panelists  
9:35-10:20   Symposium Roche: Immunotherapy in mTNBC: Today's imperative to fullfill the current unmet needs Tira Jing Ying Tan, M.D.
National Cancer Centre Singapore

Assist.Prof.THITIYA  DEJTHEVAPORN
10.20-10.40   Exhibition     
    Head and neck cancer session    
10:40-10:52 6000 Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Assist.Prof.NUTTAPONG NGAMPHAIBOON Assist. Prof.CHARUWAN AKEWANLOP
10:52-11:04 6002 TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Assist Prof. CHANYOOT  BANDIDWATTANAWONG  
11:04-11:16 6003 Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial. Assoc.Prof.PATRAPIM SUNPAWERAVONG  
11:16-11:35   Q&A  Panelists  
11:40-12:25   Symposium MSD: Emerging Therapeutic Landscape in Mutation (-) Advanced Non-small cell lung Cancer (NSCLC) :  Surein Arulananda, M.D.
Epworth Freemasons Hospital
Melbourne, Australia
 Assoc Prof. Chaiyut Charoentum
12:25-12:45   The New Immunotherapy Paradigm     
  supportive and survivor care    
12:45-12:57 11501 A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration-resistant prostate cancer. Assoc.Prof.SUTHINEE ITHIMAKIN Assoc.Prof.BUSYAMAS CHEWASKULYONG
12:57-13:09 11503 A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: J-FORCE Study. YOTSAWAJ RUNGLODVATANA, M.D.
13:09-13:21 11505 Randomized controlled trial of patient navigation intervention to increase early access to supportive care for patients with metastatic cancer in a resource-limited setting NAIYARAT PRASONGSOOK, M.D.  
13:21-13:35 Q&A  Panelists  
    Lung cancer session    
13:35-13:45 9000 RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC). Assist.Prof.THANYANAN REUNGWETWATTANA Clin.Prof. SUDSAWAT LAOHAVINIJ
13:45-13:55 9001 Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C). PIYADA SITTHIDEATPHAIBOON, M.D.  
13:55-14:05 8501 Randomized phase III study of pemetrexed/cisplatin (Pem/Cis) versus vinorelbine /cisplatin (Vnr/Cis) for completely resected stage II-IIIA non-squamous non-small-cell lung cancer (Ns-NSCLC): The JIPANG study. KULATIDA MANEENIL, M.D.  
14:05-14:25   Discussion/ Q&A  Discussant: Assoc.Prof.VIROTE SRIURANPONG , Q&A: Panelists  
14:30-15:15   Symposium AstraZeneca: Advances in management of unresectable stage III NSCLC: Where are we now? Prof.Kuo Chih-HSI
Linkou Chang Gung Memorial Hospital, Taiwan
Assoc.Prof.VIROTE SRIURANPONG
15:15-15:35   Exhibition    
  Genitourinary cancer session  
15:35-15:47 LBA2 Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial. PHICHAI CHANSRIWONG, M.D. Assoc.Prof.CHAIYUT CHAROENTUM
15:47-15:59 5006 First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). JARIN CHINDAPRASIRT, M.D.  
15:59-16:11 4502 Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810). NATTAYA  POOVORAWAN, M.D.  
16:11-16:23 4500 Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. PONGWUT DANCHIVIJITR, M.D.  
16:23-16:40 Q&A  Panelists  
16:40-16:45   Closing Remark Assoc.Prof.EKAPHOP SIRACHAINAN